Beam reports positive Phase 1/2 results for base-edited sickle cell therapy on November 11, 2026 Anemia, Sickle Cell Application procedure Base Editing Beacon Beam Therapeutics BEAM-101 risto-cel United States Food and Drug Administration vaso-occlusive crises +